ReviewCurrent urology reports2021
Techniques and Outcomes of MRI-TRUS Fusion Prostate Biopsy.
Review in Current urology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Image-fusion-guided focal irreversible electroporation for prostate cancer: Step-by-step technique.BJUI compass · 2026Article
- A retrospective study comparing multimodal fusion biopsy and conventional cognitive fusion biopsy for diagnosing prostate cancer.BMC urology · 2026Article
- Comparable recurrence risk for MRI-detected Gleason Grade Group (GG) 2 and systematic biopsy-detected GG1 prostate cancer.BJU international · 2026Article
- Decade-long landscape of transrectal ultrasound (TRUS) in prostate cancer research: trends, collaborations, and emerging frontiers.Journal of ultrasound · 2025Article
- Bibliometric analysis of magnetic resonance imaging-ultrasound fusion in prostate biopsy: trends and collaborations (2000-2024).Lasers in medical science · 2025Review
- Fusion MRI/Ultrasound-Guided Transperineal Biopsy: A Game Changer in Prostate Cancer Diagnosis.Journal of clinical medicine · 2025Review
- Evaluation of a PSA and transrectal prostate ultrasound video-based machine learning model as a tool for prostate cancer diagnosis.Frontiers in oncology · 2025Article
- Discrepancies in volume: impact of Artemis segmented magnetic resonance imaging, ultrasound, and ExactVu measurements on prostate specific antigen density and National Comprehensive Cancer Network risk stratification.Central European journal of urology · 2025Article
- Advances in imaging and artificial intelligence for precision diagnosis and biopsy guidance in prostate cancer.Frontiers in oncology · 2025Review
- Recent Advances in Image-Guided Tissue Sampling.Cureus · 2024Review
- Current Approach to Complications and Difficulties during Transrectal Ultrasound-Guided Prostate Biopsies.Journal of clinical medicine · 2024Review
- Reliability of Systematic and Targeted Biopsies versus Prostatectomy.Bioengineering (Basel, Switzerland) · 2023Article
- Predictors of Prostate Cancer at Fusion Biopsy: The Role of Positive Family History, Hypertension, Diabetes, and Body Mass Index.Current oncology (Toronto, Ont.) · 2023Article
- Article
- Machine learning prediction of prostate cancer from transrectal ultrasound video clips.Frontiers in oncology · 2022Article
- Precision interventional radiology.Journal of interventional medicine · 2021Article
- Multiparametric ultrasound of prostate: role in prostate cancer diagnosis.Therapeutic advances in urologyReview
- Complication rates of transrectal and transperineal prostate fusion biopsies - is there a learning curve even in high volume interventional center?International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purpose of reviewThe goal of this study is to review recent findings and evaluate the utility of MRI transrectal ultrasound fusion biopsy (FBx) techniques and discuss future directions. RECENT
findingsFBx detects significantly higher rates of clinically significant prostate cancer (csPCa) than ultrasound-guided systematic prostate biopsy (SBx), particularly in repeat biopsy settings. FBx has also been shown to detect significantly lower rates of clinically insignificant prostate cancer. In addition, a dedicated prostate MRI can assist in more accurately predicting the Gleason score and provide further information regarding the index cancer location, prostate volume, and clinical stage. The ability to accurately evaluate specific lesions is vital to both focal therapy and active surveillance, for treatment selection, planning, and adequate follow-up. FBx has been demonstrated in multiple high-quality studies to have improved performance in diagnosis of csPCa compared to SBx. The combination of FBx with novel technologies including radiomics, prostate-specific membrane antigen positron emission tomography (PSMA PET), and high-resolution micro-ultrasound may have the potential to further enhance this performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.